Published by MyelinWatch:
REMASTER (remibrutinib) · REMASTER is a Phase 3 study testing whether the oral drug remibrutinib is effective and safe for people with secondary progressive multiple sclerosis (MS). Participants are assigned to remibrutinib or placebo in the blinded main part of the study.
Remibrutinib inhibits Bruton's tyrosine kinase (BTK), a protein involved in immune-cell signalling. The trial tests its clinical effect and safety in secondary progressive MS; a proposed mechanism does not prove benefit.
Approach source: Novartis — remibrutinib mechanism; REMODEL results concern relapsing MS ↗
REMASTER is a Phase 3 study testing whether the oral drug remibrutinib is effective and safe for people with secondary progressive multiple sclerosis (MS). Participants are assigned to remibrutinib or placebo in the blinded main part of the study.
Large study to confirm benefit and safety
The current listing is open to participants.
The EU CTIS record, last checked on 25 October 2026, reported Greek country recruitment starting 18 September and named seven centres. The ClinicalTrials.gov update posted 13 October lists REMASTER overall as accepting participants and six Greek location rows labelled only “Novartis Investigative Site”. No results are posted in that REMASTER ClinicalTrials.gov record. Recruitment and location information do not establish benefit, safety or myelin repair in MS.
A person with secondary progressive MS may wish to discuss REMASTER because it tests whether remibrutinib can delay disability progression; taking part helps answer that question. No REMASTER results are posted, and the blinded main part assigns participants to remibrutinib or placebo, so neither receiving the experimental drug nor personal benefit is assured. At the 25 October CTIS check, Greece was listed as accepting participants and seven centres were named, but the relevant centre must confirm current enrolment and eligibility; no available place is guaranteed. Study participation is not approved treatment access, and Greek commercial availability or reimbursement for this use is not established.
At its 25 Oct 2026 check, the EU trial register named Greek centres and reported recruiting for Greece as a country. ClinicalTrials.gov and Novartis show Greek location rows under generic site labels; these rows have not been matched one-to-one to the named EU centres. Contact a centre to confirm current enrolment, eligibility and contact details; the country status does not confirm that every listed centre is enrolling.
Chaidari
Second Department of Neurology
EU trial register ↗ · Source checked:
Athens
Neurology Clinic
EU trial register ↗ · Source checked:
Ioannina
Neurology Clinic
EU trial register ↗ · Source checked:
Larissa
Neurology Clinic
Postal box; this is not a visit address.
EU trial register ↗ · Source checked:
Thessaloniki
Neurology Department
The study record gives number 3; the clinic FAQ gives number 1. Confirm the address with the centre. Clinic FAQ ↗
EU trial register ↗ · Source checked:
Cholargos
Neurology Department
EU trial register ↗ · Source checked:
Thessaloniki
B Neurology Clinic
EU trial register ↗ · Source checked:
The EU REMASTER record lists Greece as a country accepting participants, with a reported start on 18 September 2026. It names seven Greek centres. REMASTER compares remibrutinib with placebo in secondary progressive multiple sclerosis (MS). The date is a country-level registry report, not proof that every centre began accepting people on that day.
Source: EU Clinical Trials Information System — official EU clinical-trial registry ↗
